EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Associations between COVID‐19 therapies and outcomes in rural and urban America: A multisite, temporal analysis from the Alpha to Omicron SARS‐CoV‐2 variants

A Jerrod Anzalone iD, William H Beasley iD, Kimberly Murray, William B Hillegass iD, Makayla Schissel, Michael T Vest iD, Scott A Chapman iD, Ronald Horswell iD, Lucio Miele iD, J Zachary Porterfield iD, H Timothy Bunnell, Bradley S Price und 6 weitere

The Journal of Rural Health · 2025

DOI: 10.1111/jrh.12857 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Journal of Rural Health, 2025. Verfasst von A Jerrod Anzalone und 17 weiteren Autor:innen. Beteiligte Einrichtung: University of Nebraska Medical Center, Omaha, Nebraska, USA. Hauptthemen laut MEDLINE: COVID-19, Rural Population, SARS-CoV-2, Urban Population. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NCATS U24, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To investigate the enduring disparities in adverse COVID‐19 events between urban and rural communities in the United States, focusing on the effects of SARS‐CoV‐2 vaccination and therapeutic advances on patient outcomes.

Methods

Using National COVID Cohort Collaborative (N3C) data from 2021 to 2023, this retrospective cohort study examined COVID‐19 hospitalization, inpatient death, and other adverse events. Populations were categorized into urban, urban‐adjacent rural (UAR), and nonurban‐adjacent rural (NAR). Adjustments included demographics, variant‐dominant waves, comorbidities, region, and SARS‐CoV‐2 treatment and vaccination. Statistical methods included Kaplan‐Meier survival estimates, multivariable logistic, and Cox regression.

Findings

The study included 3,018,646 patients, with rural residents constituting 506,204. These rural dwellers were older, had more comorbidities, and were less vaccinated than their urban counterparts. Adjusted analyses revealed higher hospitalization odds in UAR and NAR (aOR 1.07 [1.05–1.08] and 1.06 [1.03–1.08]), greater inpatient death hazard (aHR 1.30 [1.26–1.35] UAR and 1.37 [1.30–1.45] NAR), and greater risk of other adverse events compared to urban dwellers. Delta increased, while Omicron decreased, inpatient adverse events relative to pre‐Delta, with rural disparities persisting throughout. Treatment effectiveness and vaccination were similarly protective across all cohorts, but dexamethasone post‐ventilation was effective only in urban areas. Nirmatrelvir/ritonavir and molnupiravir better protected rural residents against hospitalization.

Conclusions

Despite advancements in treatment and vaccinations, disparities in adverse COVID‐19 outcomes persist between urban and rural communities. The effectiveness of some therapeutic agents appears to vary based on rurality, suggesting a nuanced relationship between treatment and geographic location while highlighting the need for targeted rural health care strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Rural PopulationSARS-CoV-2Urban PopulationAdultAgedFemaleHumansMaleMiddle AgedAntiviral AgentsCOVID-19 Drug TreatmentCOVID-19 VaccinesHospitalizationRetrospective StudiesUnited States

Stichwörter der Autor:innen

COVID‐19 TherapiesMortalityNational COVID Cohort Collaborative (N3C)SARS‐CoV‐2Urban‐Rural Health

Substanzen

Antiviral AgentsCOVID-19 Vaccines

Autor:innen und Institutionen

  • University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • University of Oklahoma, Norman, Oklahoma, USA.
  • Maine Health Institute for Research, Portland, Maine, USA.
  • University of Mississippi Medical Center, Jackson, Mississippi, USA.
  • Christiana Care Health System, Newark, Delaware, USA.
  • University of Minnesota College of Pharmacy, Minneapolis, Minnesota, USA.

ORCID-Profile: A Jerrod Anzalone, William H Beasley, William B Hillegass, Michael T Vest, Scott A Chapman, Ronald Horswell, Lucio Miele, J Zachary Porterfield, Sharon Patrick, Clifford J Rosen, Susan L Santangelo, James C McClay, Sally L Hodder

Förderung

  • NIGMS NIH HHS
  • NCATS U24
  • NCATS NIH HHS
  • National Center for Advancing Translational Sciences
  • National Institute of General Medical Sciences

Zitieren

APA

Anzalone, A. J., Beasley, W. H., Murray, K., Hillegass, W. B., Schissel, M., Vest, M. T., Chapman, S. A., Horswell, R., Miele, L., Porterfield, J. Z., Bunnell, H. T., Price, B. S., Patrick, S., Rosen, C. J., Santangelo, S. L., McClay, J. C., Hodder, S. L., & National COVID Cohort Collaborative (N3C) Consortium (2025). Associations between COVID‐19 therapies and outcomes in rural and urban America: A multisite, temporal analysis from the Alpha to Omicron SARS‐CoV‐2 variants. The Journal of Rural Health. https://doi.org/10.1111/jrh.12857

Vancouver

Anzalone AJ, Beasley WH, Murray K, Hillegass WB, Schissel M, Vest MT, et al. Associations between COVID‐19 therapies and outcomes in rural and urban America: A multisite, temporal analysis from the Alpha to Omicron SARS‐CoV‐2 variants. The Journal of Rural Health. 2025. doi:10.1111/jrh.12857

BibTeX
@article{Anzalone2025,
  author = {Anzalone, A Jerrod and Beasley, William H and Murray, Kimberly and Hillegass, William B and Schissel, Makayla and Vest, Michael T and Chapman, Scott A and Horswell, Ronald and Miele, Lucio and Porterfield, J Zachary and Bunnell, H Timothy and Price, Bradley S and Patrick, Sharon and Rosen, Clifford J and Santangelo, Susan L and McClay, James C and Hodder, Sally L and National COVID Cohort Collaborative (N3C) Consortium, National COVID Cohort Collaborative (N3C) Consortium},
  title = {Associations between COVID‐19 therapies and outcomes in rural and urban America: A multisite, temporal analysis from the Alpha to Omicron SARS‐CoV‐2 variants},
  journal = {The Journal of Rural Health},
  year = {2025},
  doi = {10.1111/jrh.12857}
}
Kostenlos starten →